Literature DB >> 27834985

Clinical outcome of critically ill patients with thrombocytopenia and hypophosphatemia in the early stage of sepsis.

Evgeni Brotfain1, Andrei Schwartz, Avi Boniel, Leonid Koyfman, Matthew Boyko, Ruslan Kutz, Moti Klein.   

Abstract

BACKGROUND: Hypophosphatemia and thrombocytopenia may both be independent risk factors for the development of multiple organ failure and correlate well with the severity of sepsis. In the present study we wanted to analyze the potential clinical role and prognostic significance of both early hypophosphatemia and thrombocytopenia on clinical outcomes of critically ill ICU patients with severe sepsis.
METHODS: We analyzed the clinical data, including the outcome of critically ill ICU patients with severe sepsis who presented during a 5 year period with early hypophosphatemia and thrombocytopenia.This study was retrospective and single centre. All clinical and laboratory data was collected from the patients' ICU and hospital electronic records. All laboratory measurements were done on admission and during the ICU stay.
RESULTS: The included patients were distributed into one of three study groups based on the presence of hypophosphatemia and/or thrombocytopenia during the first 24 hours of admission to the ICU: group 1 - early hypophosphatemia; group 2 - early hypophosphatemia and thrombocytopenia and group 3 - early thrombocytopenia. The ICU mortality rate was significantly higher in groups 2 and 3 (25.9% and 22% vs. 9.3%, respectively, P = 0.034). An APACHE II > 27, a TISS > 25 following the first 24 hours of ICU stay , an age higher than 70, male gender and total parenteral nutrition were independent predictors of ICU and hospital mortality in this study population.
CONCLUSION: It may be considered that hypophosphatemia and thrombocytopenia in the early stage of sepsis, even when severe and coexisting, reflect the degree of initial illness severity of sepsis. However, further investigations need to be done for a better understanding of the potential clinical role of these features in the septic critically ill population.

Entities:  

Keywords:  hypophosphatemia; outcome; sepsis; septic shock; severe sepsis; thrombocytopenia

Mesh:

Year:  2016        PMID: 27834985     DOI: 10.5603/AIT.a2016.0053

Source DB:  PubMed          Journal:  Anaesthesiol Intensive Ther        ISSN: 1642-5758


  6 in total

Review 1.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

2.  Significance of Hypophosphatemia in Patients with Pneumonia.

Authors:  Yasuhiro Morimoto; Takashi Ishiguro; Ryuji Uozumi; Kenji Takano; Yoichi Kobayashi; Yasuhito Kobayashi; Yoshihiko Shimizu; Noboru Takayanagi
Journal:  Intern Med       Date:  2022-04-01       Impact factor: 1.282

3.  Effect of Serum Phosphate on the Prognosis of Septic Patients: A Retrospective Study Based on MIMIC-IV Database.

Authors:  Zhaoyang Li; Tingwen Shen; Yi Han
Journal:  Front Med (Lausanne)       Date:  2022-03-08

4.  Linezolid in the treatment of severe intraabdominal infection: A STROBE-compliant retrospective study.

Authors:  Deyuan You; Yuexiang Su; Xuri Sun; Jianbao Wang; Yuxin Zheng; Yuqi Liu
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

5.  Serum Lactate Dehydrogenase to Phosphate Ratio as an Independent Predictor for Adverse Outcome of Microsurgical Clipping for Ruptured Intracranial Aneurysm: A Propensity-Score Matching Analysis.

Authors:  Shufa Zheng; Yibin Zhang; Haojie Wang; Xueling Xie; Yuanxiang Lin; Peisen Yao; Zhangya Lin; Dezhi Kang
Journal:  Brain Sci       Date:  2022-06-04

6.  Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock.

Authors:  Shmeylan A Al Harbi; Hasan M Al-Dorzi; Albatool M Al Meshari; Hani Tamim; Sheryl Ann I Abdukahil; Musharaf Sadat; Yaseen Arabi
Journal:  BMC Pharmacol Toxicol       Date:  2021-05-28       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.